Literature DB >> 25394783

Evaluation of HAAH/humbug quantitative detection in the diagnosis of hepatocellular carcinoma.

Tian Xue1, Jing Su2, Hongmin Li1, Xiaoping Xue3.   

Abstract

Human aspartyl-(asparaginyl)-β-hydroxylase (HAAH) is a type 2 transmembrane protein and an α-ketoglutarate-dependent dioxygenase that can stereospecifically catalyze the post-translational hydroxylation reaction of β-carbon atoms of aspartic acid and asparagine residues present in epidermal growth factor-like domains of certain specific proteins. Humbug is a truncated isoform of aspartyl (asparaginyl) β-hydroxylase that lacks the catalytic domain. A series of reports demonstrated that overexpression of HAAH/humbug was identified in hepatocellular carcinoma (HCC) and various tumor tissues. However, the prognostic value of HAAH/humbug expression in HCC remains unclear. The purpose of this study was to investigate the expression of the HAAH/humbug gene at the mRNA and protein levels in HCC and to assess the overexpression of HAAH/humbug as a diagnostic and prognostic marker in HCC. HAAH/humbug mRNA levels were measured in 120 HCCs and 40 paired non-tumor liver tissues by molecular beacon (MB) quantitative RT-PCR. Immunohistochemical staining was used to detect the protein level of the HAAH/humbug in the same specimens. ROC analysis was performed based on the expression levels of the HAAH/humbug gene in 120 cases of HCC tissues and 40 cases of adjacent non-tumor liver tissues. The results showed that 117 (97.5%) of the 120 frozen sections of patients with HCCs had HAAH/humbug-positive immunoreactivity, whereas the 40 adjacent non-tumor liver tissues exhibited no staining. Higher levels of HAAH/humbug mRNA were found in 114 (95%) of the 120 HCC tissues relative to the adjacent cancer‑free tissue. ROC curve analysis exhibited that the sensitivity was 90.1%, specificity was 97.6% and ROC AUC was 0.986. The specific value of HAAH/β-actin abundance used as a cut‑off point was 0.315, while the gene copy number (7.35 copies/µl) was used a as cut‑off point, with sensitivity being 99.2%, specificity 96.7% and the ROC AUC used 0.990. No statistically significant difference was observed for these two factors. HAAH/humbug expression levels were upregulated in almost all the HCC tissues when compared to the adjacent cancer-free tissue, irrespective of the cut‑off point used. Results of the present study suggested that HAAH/humbug is a potential diagnostic and prognostic biomarker for the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394783     DOI: 10.3892/or.2014.3606

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential.

Authors:  Ting Huyan; Qi Li; Dan-Dan Dong; Hui Yang; Xiao-Ping Xue; Qing-Sheng Huang
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

2.  Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target.

Authors:  Noa G Holtzman; Michael S Lebowitz; Rima Koka; Maria R Baer; Kanam Malhotra; Amir Shahlaee; Hossein A Ghanbari; Søren M Bentzen; Ashkan Emadi
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

3.  Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen.

Authors:  Michael Babich; Ankit Sharma; Tianhong Li; James A Radosevich
Journal:  Heliyon       Date:  2022-02-21

4.  Optimized Expression and Purification of Humbug in Pichia pastoris and Its Monoclonal Antibody Preparation.

Authors:  Ting Huyan; Ruihua Tang; Jing Li; Qi Li; Xiaoping Xue; Hui Yang
Journal:  Iran J Public Health       Date:  2015-12       Impact factor: 1.429

Review 5.  Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).

Authors:  Wenqian Zheng; Xiaowei Wang; Jinhui Hu; Bingjun Bai; Hongbo Zhu
Journal:  Oncol Rep       Date:  2020-10-06       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.